Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2022

View Archived Issues

Novel Fanconi anemia xenograft murine model to test immunotherapy

Allorion Therapeutics presents TYK2 inhibitor ARTS-011 for the treatment of inflammatory disease

Autoantibody-induced murine dry eye disease model mimics human disease

Novel Nr1h3-/- mouse model exhibits AMD-like pathology

MFAP4 as a novel target in choroidal neovascularization

Across body parts, "parts list" gives insights into the lives of a cell

Chinese investigators patent new HIF inhibitors

Medivir and Rheos Medicines divulge new MALT1 inhibitors

U.S. researchers describe new PROTACs for cancer

Johns Hopkins University synthesizes MAP3K12/13 inhibitors

Chinese researchers disclose new CDK9 inhibitors

Kymera presents preclinical data on STAT3 degrader KTX-115

VERVE-101 shows durable editing of PCSK9 gene; GalNAc-LNPs improve delivery of base editors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...